Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 14638974.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors report a retrospective analysis of the use of mycophenolate mofetil (MyM) in 85 patients with autoimmune myasthenia gravis. The Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) was used to characterize the treatment response in each patient. Sixty-two patients (73%) achieved a PIS status indicating improvement. Quantitative strength testing performed on the majority of patients before and after treatment also improved. Side effects to MyM were observed in 27% of patients but required discontinuation in only 6%.
Medical subject headings
- Immunosuppressive Agents
- Myasthenia Gravis
- Mycophenolic Acid